Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Contributing writer

Rebecca Nguyen, MB, BS, FACD
Skin and Cancer Foundation, Monash Health and Eastern Health
Melbourne, Australia

Rebecca Nguyen is a consultant dermatologist at the Skin and Cancer Foundation, Monash Health and Eastern Health, Melbourne, Australia. She completed her dermatology training in 2016 and has published as lead author on 8 peer-reviewed manuscripts. Dr. Nguyen is a 2019 IPC International Fellow and as part of her yearlong fellowship will work with IPC Professor Carle Paul in the dermatology department of Paul Sabatier University in Toulouse, France.

Last Updated: Aug 13, 2019

  

Latest news

July 22, 2020
Paolo Gisondi et al., summarize issues faced by many dermatologists during the unprecedented lockdown period in Spring 2020 due to the COVID-19 pandemic. Issues like the sudden cancellation of face-to-face consultations, and the mandatory introduction of telemedicine (after months of a rather optional exercise with this type of caregiving), needed an entrepreneurial approach to manage.
July 20, 2020
Eli Lilly and Company (NYSE:LLY) announced today that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study. OASIS-2 is a multicenter randomized, double-blind, placebo-controlled study comparing the efficacy and safety of mirikizumab to placebo and Cosentyx in patients with moderate to severe plaque psoriasis.
July 14, 2020
Dr. Stingl discusses differences in the pathogenesis of plaque psoriasis and pustular psoriasis. Spoiler alert: it's the neutrophils.
July 09, 2020
PsoProtectMe now available in multiple languages
  More News

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK